Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.

Become a Member

Membership

The SFPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits

Applications for membership may be submitted at any time during the year. We look forward to having you onboard!

Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series should not be missed for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Next Seminar

Wednesday, February 8, 2023 @ 11:30 AM EST

Meeting URL: dfci.zoom.us
Meeting ID: 932 5793 1032 | Password: 153772

NOTE: UPDATED ZOOM INFORMATION

Clifford Reid
Clifford Reid
Travera, Inc.
A New Technology for Rapid Cancer Therapy Guidance

Recent News

Stay connected, stay ahead. Know everything that matters, as it happens. From the very latest industry news, reports, papers, and studies. Would you like to see your news here? Email the admin and we will get it linked. Check out our news archive for all past stories and posts.

An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
January 13, 2023

An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma

Patients with non-Hodgkin’s lymphomas (NHLs) often relapse after frontline treatment, and interpatient heterogeneity make personalized combination treatment difficult. Goh et al. have developed a hybrid experimental-analytic method that they call quadratic phenotypic optimization platform, or QPOP, to identify personalized drug combination therapies using ex vivo patient samples to improve patient outcomes. In a prospective cohort, physicians were able to alter treatment according to drug combinations identified using QPOP after 6 days to achieve complete responses in 5 of 17 patients with NHL. This is a promising step for providing new hope for patients who have relapsed NHL and provides a foundation for further clinical trials.

Read MORE
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
December 20, 2022

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

A follow up to our October Seminar

The BCL2 inhibitor venetoclax has revolutionized the treatment of AML patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly for R/R AML. Although, the ex vivo drug sensitivity testing has been used by several research groups, very few prospective trials have analyzed the correlation of drug sensitivity testing results to treatment outcome

VenEx is a prospective Phase 2 trial aiming to evaluate if ex vivo drug sensitivity testing could be used to identify AML patients who benefit from venetoclax + azacitidine therapy. This interim analysis of 39 first trial participants demonstrated that the experimental conditions significantly influenced predictive accuracy. Blast-specific venetoclax sensitivity measured in conditioned medium most accurately correlated with treatment outcomes; 88% of sensitive participants achieved treatment response. Median survival was significantly longer for ex vivo sensitive participants. This analysis illustrates the feasibility of integrating drug-response profiling into clinical practice and demonstrates excellent predictivity. The second stage of the trial is on-going to validate these results.

Read MORE
The American Society of Hematology Webinar
October 11, 2022

The American Society of Hematology Webinar

The American Society of Hematology welcomes SFPM President Dr. Tony Letai, Dr. Philipp Staber, & Dr. Caroline Heckman to discuss "Functional Precision Hematology" at their October 11 webinar.

Read MORE
SFPM comment on rule NCD190.8
September 2, 2022

SFPM comment on rule NCD190.8

The SFPM has submitted a comment on CMS rule NCD190.7, which currently acts as a barrier to reimbursement for functional precision medicine assays in the United States. We propose that this outdated rule be retired so that assays can be individually assessed by local Medicare Administrative Contractors for reimbursement. If you agree with this statement, either as an individual or a company in the FPM space, please consider adding your own comment here. Note that comments are being accepted only through Tuesday, September 6, so time is short.

Read MORE
Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia
August 25, 2022

Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia

Phosphatidylinositol 3-kinase inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). While patients may show an initial response to these therapies, development of treatment intolerance or resistance remains clinical challenges. To overcome these, prediction of individual treatment responses based on actionable biomarkers is needed. Here, we characterized the activity and cellular effects of ten PI3Ki and investigated whether functional analyses can identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki.

Read MORE
Precision Medicine and Therapeutic Resistance Collection
June 28, 2022

Precision Medicine and Therapeutic Resistance Collection

Check out this great collection of Precision Medicine and Therapeutic Research curated by Cancer Discovery editors selected from the Journal. Some of these select original research articles are followed by their corresponding In the Spotlight commentaries, which serve to place them in the context of their field

Read MORE

Support the SFPM

The SFPM is growing, and we need financial support. While we collect annual individual membership dues, these only fund a fraction of our needs. To plan for the future, the SFPM must secure a stable financial basis from which to plan. Even though the Board is made up of unpaid volunteers, we nonetheless have significant costs to defray, particularly with respect to annual meetings and administrative support.

Contributions from all tiers will be recognized by name on the SFPM website, however, contributions at the Precision tier will receive preferred logo placement and recognition on the SFPM website, logo and name recognition at each monthly seminar, and institution name and logo prominently displayed at our annual meeting and on meeting marketing materials. Precision tier supporters will also receive ten (10) complimentary memberships to be distributed amongst their institutions. Functional tier supporters will receive name and logo recognition during at least six of our monthly seminars as well as name and logo recognition on our website. Functional tier supporters will also receive five (5) complimentary memberships to be distributed amongst their institutions. Advocate tier supporters will receive name and logo recognition on our website and one (1) complimentary membership. We hope you agree with us that “the future is functional”, and that the SFPM is getting us there faster.

Thank You Sponsors